脊柱立体定向放射外科治疗肝胆恶性肿瘤转移:PRISM评分辅助患者选择
本研究回顾性分析2004至2017年单中心28例肝胆恶性肿瘤脊柱转移患者共43处病灶接受脊柱立体定向放射外科(SSRS)的疗效。1年局部控制率85%、总生存率23%,中位至死亡时间6.2个月,中位至局部失败未达到。肿瘤体积>60 cc和Bilsky≥1c预测局部控制更差,PRISM分组与系统性疾病进展与更差生存相关。
要点
- SSRS对肝胆恶性肿瘤脊柱转移可提供持久局部控制,1年局部控制率85%。
- 肿瘤体积>60 cc和Bilsky≥1c与更差局部控制相关。
- PRISM分组与系统性疾病进展是生存的独立预测因素。
核心结论
- SSRS对肝胆恶性肿瘤脊柱转移患者提供持久局部控制,需要更高BED以确保优良局部控制。
- PRISM评分是有前景的预后工具,可辅助SSRS患者选择。
研究设计与样本
- 单中心回顾性研究,纳入2004至2017年接受SSRS治疗的肝胆恶性肿瘤脊柱转移患者28例共43处病灶。
- 采用Kaplan-Meier法计算总生存和局部控制,Cox回归分析识别与疾病相关结局相关的因素。
主要发现
- 1年局部控制率为85%,1年总生存率为23%。
- 中位至死亡时间为6.2个月,中位至局部失败时间未达到。
- 肿瘤体积>60 cc(SHR 6.65,p=0.03)和Bilsky≥1c(SHR 4.73,p=0.05)预测更差局部控制,BED10>81 Gy趋势 towards 更好局部控制(SHR 4.35,p=0.08)。
- 单因素分析中Child-Pugh分级(HR 3.02,p=0.003)、更高PRISM分组(HR 3.49,p=0.001)和系统性疾病进展(HR 3.65,p=0.001)与更差生存相关;多因素分析中PRISM分组(HR 2.28,p=0.03)和系统性疾病进展(HR 2.67,p=0.03)仍显著。
- 4例患者(10%)出现压缩性畸形,1例患者(2%)出现放射性神经炎。
关键数值与推荐
- 1年局部控制率85%,1年总生存率23%。
- 中位至死亡时间6.2个月,中位至局部失败时间未达到。
- 肿瘤体积>60 cc:SHR 6.65,p=0.03;Bilsky≥1c:SHR 4.73,p=0.05;BED10>81 Gy:SHR 4.35,p=0.08。
- Child-Pugh分级:HR 3.02,p=0.003;PRISM分组:HR 3.49,p=0.001(单因素),HR 2.28,p=0.03(多因素);系统性疾病进展:HR 3.65,p=0.001(单因素),HR 2.67,p=0.03(多因素)。
- 压缩性畸形发生率10%(4例),放射性神经炎发生率2%(1例)。
临床怎么用
- 对于肝胆恶性肿瘤脊柱转移患者,SSRS可实现持久局部控制,但需权衡更高BED与脊髓邻近的限制。
- PRISM评分可辅助筛选适合SSRS的患者,高分患者生存更差,需综合系统性疾病状态决策。
- 肿瘤体积>60 cc和Bilsky≥1c患者局部控制更差,应考虑强化局部治疗或密切随访。
局限性
- 单中心回顾性研究,样本量较小(28例患者,43处病灶)。
- 中位至局部失败时间未达到,局部控制数据尚不成熟。
- BED10>81 Gy仅显示趋势(p=0.08),未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dose escalation via stereotactic radiation therapy techniques has been necessary for hepatobiliary malignancies in the primary and oligometastatic setting, but such dose escalation is challenging for spine metastases due to spinal cord proximity. Here, we investigate the role of spine stereotactic radiosurgery (SSRS) in the management of such metastases. METHODS: We retrospectively reviewed patients treated with SSRS to spinal metastases from hepatobiliary malignancies between 2004 and 2017 at our Institution. We used the Kaplan-Meier method to calculate overall survival (OS) and local control (LC) and Cox regression analysis to identify factors associated with disease-related outcomes. RESULTS: We identified 28 patients treated to 43 spinal metastases with SSRS for either HCC or cholangiocarcinoma. The 1-year LC and OS were 85% and 23%, respectively. The median time to death was 6.2 months, while median time to local failure was not reached. Tumor volume > 60 cc (SHR 6.65, p = 0.03) and Bilsky ≥ 1c (SHR 4.73, p = 0.05) predicted for poorer LC, while BED10 > 81 Gy trended towards better local control (SHR 4.35, p = 0.08). Child-Pugh Class (HR 3.02, p = 0.003), higher PRISM Group (HR 3.49, p = 0.001), and systemic disease progression (HR 3.65, p = 0.001) were associated with worse mortality based on univariate modeling in patients treated with SSRS; on multivariate analysis, PRISM Group (HR 2.28, p = 0.03) and systemic disease progression (HR 2.67, p = 0.03) remained significant. Four patients (10%) developed compression deformity and one patient (2%) developed radiation neuritis. CONCLUSION: SSRS provides durable local control in patients with metastatic hepatobiliary malignancies, with higher BED necessary to ensure excellent LC. PRISM scoring is a promising prognostic tool to aid SSRS patient selection.
引用
- Gjyshi O, Boyce-Fappiano D, Pezzi TA, et al. Spine stereotactic radiosurgery for metastases from hepatobiliary malignancies: patient selection using PRISM scoring. J Neurooncol. 2020. PMID: 32358642. doi:10.1007/s11060-020-03522-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。